Can manufacturers owe duties to end-users for equipment installation? Alder v. Bayer Corp. Explained

The Utah Supreme Court’s decision in Alder v. Bayer Corp. provides crucial guidance for appellate practitioners handling toxic tort cases involving equipment manufacturers and their duties to end-users. This case demonstrates how tort duties can arise even when contractual arrangements appear to allocate responsibilities elsewhere.

Background and Facts

Two radiography technicians at LDS Hospital developed severe health problems after AGFA relocated its Curix x-ray processing machine to a new, poorly ventilated mammography suite. The technicians had used the same machine for years without problems in other locations. AGFA’s safety specifications required ten complete air exchanges per hour, but the new room had only two. When technicians complained of symptoms including voice loss, chest tightness, and cognitive deficits, AGFA installed a vent kit but never tested the ventilation system’s adequacy.

Key Legal Issues

The court addressed three primary issues: (1) whether AGFA owed a duty of care to the technicians under tort law; (2) whether conditions like chronic fatigue syndrome and fibromyalgia constitute legally cognizable injuries separate from the controversial diagnosis of multiple chemical sensitivity; and (3) whether expert testimony based on differential diagnosis is admissible without precise proof of toxic exposure levels.

Court’s Analysis and Holding

The Utah Supreme Court reversed summary judgment, holding that AGFA owed duties under three Restatement provisions. Under section 324A, AGFA’s undertaking to install and maintain equipment for technicians’ safety created liability when its failure to ensure adequate ventilation increased the risk of harm. Under section 388, as a supplier knowing the equipment’s dangerous potential without proper ventilation, AGFA had duties to inform users and safeguard against dangers. The court also applied section 389, finding AGFA knew the machine was unlikely to be made reasonably safe before use.

Regarding expert testimony, the court distinguished between the controversial diagnosis of multiple chemical sensitivity—properly excluded—and the medically accepted conditions of chronic fatigue syndrome, fibromyalgia, and cognitive deficits. The court emphasized that differential diagnosis is a standard, widely accepted scientific technique not subject to heightened reliability tests under Rimmasch.

Practice Implications

This decision significantly impacts toxic tort litigation strategy. When challenging expert testimony exclusions, practitioners should separately analyze each medical condition rather than allowing courts to group all symptoms under one controversial umbrella diagnosis. The court’s adoption of Restatement sections 324A and 389 expands potential liability theories for equipment manufacturers who undertake installation and maintenance services. Additionally, the decision confirms that temporal relationships between exposure and illness, combined with differential diagnosis methodology, can support causation even without precise exposure measurements.